Breast Cancer | Specialty

FDA Approves PD-L1 IHC 22C3 pharmDx as Companion Diagnostic for Pembrolizumab in TNBC

November 16th 2020

November 16, 2020 — The FDA has approved the PD-L1 IHC 22C3 pharmDx to aid in the identification of patients with triple-negative breast cancer who are eligible to receive the PD-1 inhibitor pembrolizumab.

Fixed-Dose Pertuzumab/Trastuzumab Combo Nears EU Approval for HER2+ Breast Cancer

November 15th 2020

November 15, 2020 - The European Medicines Agency’s Committee for Medicinal Products for Human Use has adopted a positive opinion for the fixed-dose combination of pertuzumab plus trastuzumab with hyaluronidase-zzxf for administration via subcutaneous injection in combination with intravenous chemotherapy in the treatment of patients with early and metastatic HER2-positive breast cancer

FDA Approves Pembrolizumab/Chemo for Locally Recurrent Unresectable or Metastatic TNBC

November 13th 2020

November 13, 2020 - The FDA has granted an accelerated approval to pembrolizumab for use in combination with chemotherapy in the treatment of patients with locally recurrent unresectable or metastatic triple-negative breast cancer whose tumors express PD-L1 as determined by an FDA-approved test.

Pembrolizumab Shows Intriguing Benefit in Leptomeningeal Metastasis From Solid Tumors

November 12th 2020

November 12, 2020 — Pembrolizumab led to a 38% central nervous system response rate and was well tolerated in patients with leptomeningeal metastasis from solid tumors. However, the study was closed early due to poor accrual.

Dr. Krop on the Role of Neratinib as Extended Adjuvant Therapy in HR+/HER2+ Breast Cancer

November 9th 2020

Ian E. Krop, MD, PhD, discusses the role of neratinib as extended adjuvant therapy in high-risk, hormone receptor–positive, HER2-positive breast cancer.

Tripathy Talks Genomics, Targeted Treatments, and Smart Trial Designs in Breast Cancer

November 6th 2020

In our exclusive interview, Debu Tripathy, MD, considers the biological and long-term outcome variability of HR-positive, HER2-negative breast cancer and details the research that is being done to develop personalized treatment approaches.

Dr. Jhaveri on Outlining First-Line Treatment in HER2+ Breast Cancer

November 5th 2020

Komal Jhaveri, MD, FACP, discusses the importance of outlining the first-line treatment course for patients with HER2-positive breast cancer.

Novel Combinations Carry CDK4/6 Inhibitors Into the Future in HR+/HER2- Breast Cancer

November 5th 2020

Patients with advanced hormone receptor–positive, HER2-negative breast cancer still face acquired resistance, even with the most effective agents, namely CDK4/6 inhibitors, which have demonstrated unprecedented overall survival benefit in the metastatic setting.

Immunotherapy, ADCs, PARP Inhibitors Make Waves in Metastatic TNBC

November 3rd 2020

Candace Mainor, MD, discusses novel approaches that are generating excitement in metastatic triple-negative breast cancer.

CDK4/6, PI3K Inhibition Among Top Advances Made in Metastatic Breast Cancer Treatment

November 3rd 2020

Julie M. Collins, MD, MPH, highlights key updates with targeted agents such as CDK4/6 and PI3K inhibitors in the treatment of patients with hormone receptor–positive breast cancer.

TNBC Advances Feature Immunotherapy, PARP Inhibitors, and ADCs

November 3rd 2020

Kari B. Wisinski, MD, discusses the evolving roles of immunotherapy, ADCs, and PARP inhibitors in triple negative breast cancer.

I-SPY2: A Revolutionary Effort to Advance Personalized Care in Breast Cancer

November 3rd 2020

Claudine J. Isaacs, MD, discusses significant advances that have been made across all different breast cancer subtypes in recent years, as well as ongoing research efforts.

Tan Speaks to Benefits of Fixed-Dose Pertuzumab/Trastuzumab Combo in HER2+ Breast Cancer

October 30th 2020

Antoinette R. Tan, MD, discusses the FDA approval of the fixed-dose combination of SC pertuzumab and trastuzumab with hyaluronidase, in combination with IV chemotherapy in HER2-positive breast cancer.

ESMO 2020 Highlights With Aditya Bardia, MD, MPH

October 29th 2020

Aditya Bardia, MD, MPH, discusses the results of the ASCENT trial in triple-negative breast cancer.

Dr. Tripathy on Treatment De-Escalation in HER2+ Breast Cancer

October 28th 2020

Debu Tripathy, MD, discusses treatment de-escalation in HER2-positive breast cancer.

Dr. Gradishar on the Expanding Role of Trastuzumab Deruxtecan in HER2+ Breast Cancer

October 28th 2020

William J. Gradishar, MD, discusses the expanding role of fam-trastuzumab deruxtecan-nxki in HER2-positive breast cancer.

Dr. Isaacs on the Evolving Treatment Landscape in HER2+ Breast Cancer

October 27th 2020

Claudine Isaacs, MD, discusses the rapidly evolving HER2-positive breast cancer armamentarium.

Future Directions for Treatment of TNBC

October 23rd 2020

Phase 3 ASCENT Trial in mTNBC: Managing Adverse Events

October 23rd 2020

Phase 3 ASCENT Trial in mTNBC

October 23rd 2020